SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 and 15(d) of
                       the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):                  June 15, 2001


                         Human Pheromone Sciences, Inc.
         ---------------------------------------------------------------
             (Exact name of Registrant as specified in its charter)



          CALIFORNIA                     0-23544            94 -3107202
  --------------------------          -------------       ---------------
(State or other jurisdiction           (Commission         (IRS Employer
      of incorporation)                File Number)      Identification No.)



84 West Santa Clara Street, Suite 720, San Jose, California          95113
-----------------------------------------------------------         --------
     (Address of principal executive offices)                      (Zip code)


Registrant's telephone number, including area code:         (408) 938-3030
                                                           ----------------


               46750 Fremont Boulevard, Fremont, California 94538
            --------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)






                    INFORMATION TO BE INCLUDED IN THE REPORT

ITEM 4.  CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANTS

         The Audit  Committee of the Company  authorized the  termination of BDO
         Seidman LLP as auditors of the Company  effective  June 15,  2001.  The
         reports of BDO Seidman LLP on the Company's  financial  statements  for
         the past two  fiscal  years did not  contain  an  adverse  opinion or a
         disclaimer  of  opinion  and  were  not  qualified  or  modified  as to
         uncertainty, audit scope, or accounting principles.

         In connection with the audits of the Company's financial statements for
         each of the two  fiscal  years  ended  December  31,  2000,  and in the
         subsequent  interim  period  through  the date  hereof,  there  were no
         disagreements  with  BDO  Seidman  LLP on  any  matters  of  accounting
         principles or practices,  financial statement  disclosure,  or auditing
         scope and procedures  which, if not resolved to the satisfaction of BDO
         Seidman LLP would have caused BDO Seidman LLP to make  reference to the
         matter in their  report.  The Company has  requested BDO Seidman LLP to
         furnish it a letter  addressed  to the  Commission  stating  whether it
         agrees with the above statements. A copy of that letter, dated June 20,
         2001, is filed as Exhibit 7.1 to this Form 8-K.

ITEM 7   FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

         Exhibit 7.1 - Letter from BDO Seidman LLP  pursuant to Item 304 (a) (3)
         of Regulation S-K.





                                    SIGNATURE

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                            HUMAN PHEROMONE SCIENCES, INC.



                                      By: /s/ William P. Horgan
                                      ------------------------------------------
                                      William P. Horgan, Chief Executive Officer